Affiliation:
1. Department of Cutaneous Oncology, Moffitt Canter, Tampa, FL 33612, USA
Abstract
Treatment of soft tissue sarcomas (STSs) is complicated by disease heterogeneity. Further, it has not benefitted much from the recent therapeutic advances in other soft tissue malignancies. Surgical resection remains the gold standard in resectable disease, but unresectable, locally advanced STS requires alternative and multimodal approaches. Isolated limb infusion (ILI) provides regional chemotherapy to extremity STS and offers the potential for limb salvage. Despite being in use for nearly 3 decades, there is limited literature on ILI in STS. This review provides an overview of patient eligibility, the procedure, significant publications in this field, and opportunities for further progress.
Reference29 articles.
1. Fletcher, C., Bridge, J.A., Hogendoorn, P.C.W., and Mertens, F. (2013). WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, World Health Organization.
2. Immunotherapy in soft-tissue sarcoma;Ayodele;Curr. Oncol.,2020
3. Lessons learned from the study of 10,000 patients with soft tissue sarcoma;Brennan;Ann. Surg.,2014
4. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma?;Gustafson;Cancer,1990
5. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy;Rosenberg;Ann. Surg.,1982
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献